Bullish Moving Averages
16
Bearish Moving Averages
0
Back Stocks profile
Stock analysis tool for investors
Performance
Today’s low
104.40Today’s High
104.4052W low
75.9052W High
124.40Open Price
104.40Prev. Close
82.4000Volume
17821.00Value
1861403.45Fundamentals
Market Cap Cr
247.10
Price to Earnings
21.90
Price to Book Value
3.40
Dividend Yield
0.00
PE to Growth
0.20
Op Revenue TTM Cr
153.31
Net Profit TTM Cr
11.26
Cash From Operating Activity Cr
4.95
Return on Equity %
15.43
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
03 May, 2024
100
Week
100
Month
100
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
104.45
PIVOT
First Resistance
104.45
Second Resistance
104.45
Third Resistance
104.45
First Support
104.45
Second Support
104.45
Third Support
104.45
Relative Strength Index
76.77
Money Flow Index
83.78
MACD
2.85
MACD Signal
1.07
Average True Range
3.93
Average Directional Index
21.89
Rate of Change (21)
30.16
Rate of Change (125)
21.1
Commodity Channel Index
304.2
Williams %R
BETA
1 Month
0.34
3 Month
0.51
1 Year
0.11
3 Year
0.19
PRICE CHANGE ANALYSIS
↑ 21.45%
1 Week
Low
High
88.95
104.45
↑ 18.09%
1 Month
Low
High
83.25
104.45
↑ 6.36%
3 Months
Low
High
75.9
104.45
↑ 23.24%
6 Months
Low
High
75.9
107.8
↑ 28.24%
1 Year
Low
High
75.9
124.45
| Indicator | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 29.42 | 40.84 | 43.82 | 42.50 | 35.63 | 22.60 | 18.23 | 16.25 | 20.95 | 28.62 | 21.43 | |
| Operating Expenses Qtr | 30.52 | 36.67 | 35.65 | 34.62 | 30.67 | 19.42 | 15.27 | 15.51 | 17.63 | 22.74 | 17.77 | |
| Operating Profit Qtr | -2.08 | 4.00 | 6.30 | 7.62 | 3.55 | 2.54 | 1.66 | -0.52 | 2.83 | 5.70 | 3.48 | |
| EBIDT Qtr Cr | -1.10 | 4.16 | 8.16 | 7.88 | 4.96 | 3.18 | 2.96 | 0.55 | 3.32 | 3.91 | 3.65 | |
| Depreciation Qtr | 1.27 | 1.24 | 1.21 | 1.53 | 1.40 | 1.12 | 1.29 | 1.40 | 1.21 | 1.42 | 1.46 | |
| Net Profit Qtr | -2.94 | 2.48 | 6.35 | 5.37 | 2.99 | 1.61 | 1.36 | -1.01 | 1.70 | 2.38 | 2.09 | |
| Basic EPS Qtr | -1.24 | 1.05 | 2.68 | 2.34 | 1.26 | 0.68 | 0.57 | -0.38 | 0.72 | 0.95 | 0.88 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 118.62 | 87.24 | 71.97 | 42.73 | 44.01 | |
| Operating Expenses Annual Cr | 99.63 | 73.65 | 60.92 | 41.24 | 56.69 | |
| Operating Profit Annual | 15.72 | 11.49 | 10.30 | 1.23 | -13.34 | |
| Operating Profit Margin Annual % | 13.25 | 13.17 | 14.31 | 2.88 | -30.30 | |
| Total Expenses Annual Cr | 107.01 | 79.93 | 66.14 | 44.61 | 62.24 | |
| EBIDT Annual Cr | 18.99 | 13.59 | 11.05 | 1.48 | -12.68 | |
| EBIDT Annual margin % | 16.01 | 15.58 | 15.35 | 3.47 | -28.81 | |
| Depreciation | 5.33 | 5.49 | 4.48 | 3.27 | 3.42 | |
| PAT Before ExtraOrdinary Items Annual Cr | 11.34 | 5.15 | 5.83 | -25.20 | -19.73 | |
| Net Profit Annual | 11.34 | 5.15 | 5.83 | -25.20 | -19.73 | |
| Basic EPS Annual | 4.86 | 2.17 | 2.46 | -106.54 | -8.34 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 73.45 | 62.88 | 56.77 | -4.41 | 20.79 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 9.65 | 10.97 | 5.39 | 3.02 | 29.20 | |
| Total Current Liabilities Annual Cr | 46.48 | 16.39 | 24.31 | 17.10 | 70.65 | |
| Total Capital Plus Liabilities Annual Cr | 129.58 | 90.24 | 86.47 | 71.06 | 120.64 | |
| Fixed Assets Annual | 41.73 | 38.85 | 36.80 | 35.18 | 37.02 | |
| Total Non Current Assets Annual | 42.27 | 38.85 | 36.80 | 35.18 | 72.40 | |
| Total Current Assets Annual | 87.31 | 51.40 | 49.67 | 35.88 | 48.24 | |
| Total Assets Annual | 129.58 | 90.24 | 86.47 | 71.06 | 120.64 | |
| Contingent Liabilities plus Commitments Annual Cr | 10.48 | 2.42 | 0.00 | 0.00 | 0.00 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 4.95 | 8.03 | -13.61 | -34.27 | -1.09 | |
| Cash from Investing Activity Annual | -7.49 | -5.44 | -5.35 | 32.77 | 3.53 | |
| Cash from Financing Annual Activity | 10.18 | -4.22 | 12.28 | 7.27 | -2.44 | |
| Net Cash Flow Annual | 7.64 | -1.63 | -6.68 | 5.78 | -0.00 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 31.05 | 26.58 | 24.00 | -18.64 | 8.79 | |
| ROE Annual % | 15.43 | 8.19 | 10.26 | 0.00 | -94.88 | |
| ROCE Annual % | 16.42 | 10.96 | 10.56 | -3.30 | -32.21 | |
| Total Debt to Total Equity Annual | 0.31 | 0.13 | 0.04 | -0.68 | 2.22 | |
| EBDIT Annual Margin % | 16.46 | 15.96 | 15.51 | 3.49 | -29.24 |
| Indicator | Graph |
|---|---|
| Total Qtr Revenue cr | |
| Operating Expenses Qtr | |
| Operating Profit Qtr | |
| EBIDT Qtr Cr | |
| Depreciation Qtr | |
| Net Profit Qtr | |
| Basic EPS Qtr |
| Indicator | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 42.73 | 44.01 | 78.50 | 66.10 | 87.30 | |
| Operating Expenses Annual Cr | 41.25 | 56.70 | 82.30 | 70.77 | 84.80 | |
| Operating Profit Annual | 1.22 | -13.34 | -35.13 | -5.81 | 0.52 | |
| Operating Profit Margin Annual % | 2.86 | -30.32 | -44.75 | -8.79 | 0.59 | |
| Total Expenses Annual Cr | 44.61 | 62.31 | 93.22 | 86.46 | 102.62 | |
| EBIDT Annual Cr | 1.48 | -12.69 | -3.80 | -4.67 | 2.50 | |
| EBIDT Annual margin % | 3.46 | -28.83 | -4.84 | -7.06 | 2.86 | |
| Depreciation | 3.27 | 3.48 | 3.97 | 4.22 | 4.86 | |
| PAT Before ExtraOrdinary Items Annual Cr | -24.44 | -18.35 | -16.91 | -19.46 | -15.14 | |
| Net Profit Annual | -24.73 | -18.87 | -16.74 | -19.09 | -14.03 | |
| Basic EPS Annual | -15.52 | -11.48 | -7.15 | -10.43 | -8.80 |
| Indicator | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | -4.24 | 19.06 | 37.93 | 42.67 | 57.75 | |
| Minority Interest Liability Annual Cr | 0.08 | -0.21 | -0.73 | -0.55 | 0.00 | |
| Total Non Current Liabilities Annual Cr | 3.02 | 29.80 | 41.31 | 54.72 | 39.91 | |
| Total Current Liabilities Annual Cr | 17.10 | 70.82 | 59.85 | 81.47 | 95.05 | |
| Total Capital Plus Liabilities Annual Cr | 71.31 | 119.47 | 138.36 | 178.31 | 192.71 | |
| Fixed Assets Annual | 35.18 | 37.02 | 44.86 | 48.58 | 52.57 | |
| Total Non Current Assets Annual | 35.22 | 71.00 | 89.62 | 101.12 | 70.22 | |
| Total Current Assets Annual | 36.10 | 48.47 | 48.74 | 77.18 | 122.30 | |
| Total Assets Annual | 71.31 | 119.47 | 138.36 | 178.31 | 192.71 | |
| Contingent Liabilities plus Commitments Annual Cr | 0.00 | 0.00 | 0.46 | 0.29 | 1.64 |
| Indicator | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | -34.31 | -1.79 | -7.05 | -0.95 | 0.91 | |
| Cash from Investing Activity Annual | 32.77 | 14.93 | 37.97 | -5.42 | -0.36 | |
| Cash from Financing Annual Activity | 7.30 | -13.38 | -30.63 | 6.31 | -0.61 | |
| Net Cash Flow Annual | 5.77 | -0.24 | 0.29 | -0.06 | -0.06 |
| Indicator | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | -17.59 | 7.97 | 15.73 | 22.57 | 30.95 | |
| ROE Annual % | 0.00 | -99.01 | -44.12 | -44.73 | -24.28 | |
| ROCE Annual % | -3.29 | -33.22 | -9.90 | -9.17 | -2.41 | |
| Total Debt to Total Equity Annual | -0.71 | 2.43 | 1.23 | 1.93 | 1.39 | |
| EBDIT Annual Margin % | 3.48 | -29.26 | -8.05 | -7.18 | 2.92 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| SRJR LIFESCIENCES LLP | 87.86 | 75289927 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|
| Name | Holding Percent | Holding Id |
|---|---|---|
| MONARCH NETWORTH FINSERVE PRIVATE LIMITED | 1.35 | 75289934 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Sep 19, 2013 | 0.6 | FINAL | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|
| Ex-Date | Purpose | Notes |
|---|---|---|
| Feb 12, 2024 | Quarterly Results | - |
| Nov 09, 2023 | Quarterly Results | - |
| Aug 11, 2023 | Quarterly Results | - |
| May 27, 2023 | Audited Results | (Revised) |
| Apr 07, 2023 | Others | - |
| Feb 08, 2023 | Quarterly Results | - |
| Nov 11, 2022 | Quarterly Results | - |
| Aug 11, 2022 | Quarterly Results | - |
| May 26, 2022 | Audited Results | - |
| Feb 10, 2022 | Quarterly Results | - |
| Nov 12, 2021 | Quarterly Results & Rights issue | Inter alia, To consider and approve the proposal for various avenues for raising funds, including and in particular Rights Issue to meet capital requirements of the Company. |
| Sep 16, 2021 | Others | Inter alia, to consider the proposal of availing working capital / term loan facility for expansion program and any other business with the permission of the Chair. |
| Aug 05, 2021 | Quarterly Results | - |
| Jun 25, 2021 | Audited Results | - |
| Feb 12, 2021 | Quarterly Results | - |
| Nov 12, 2020 | Quarterly Results | - |
| Sep 10, 2020 | Quarterly Results | - |
| Jun 25, 2020 | Audited Results | - |
| Feb 13, 2020 | Quarterly Results | - |
| Nov 13, 2019 | Quarterly Results | - |
| Aug 10, 2019 | Quarterly Results | - |
| May 27, 2019 | Audited Results | - |
| Feb 08, 2019 | Quarterly Results | - |
| Nov 13, 2018 | Quarterly Results | - |
| Sep 05, 2018 | Other business matters | - |
| Aug 13, 2018 | Unaudited Financial Results | - |
| May 28, 2018 | Audited Results | - |
| Feb 12, 2018 | Quarterly Results | - |
| Nov 10, 2017 | Quarterly Results | - |
| Aug 08, 2017 | Quarterly Results | - |
| May 27, 2017 | Audited Results | - |
| Mar 14, 2017 | Others | 1. To consider and approve PRIVATE PLACEMENT OFFER LETTER (Form PAS-4). |
| Feb 04, 2017 | Quarterly Results | - |
| Jan 07, 2017 | Others | To consider and propose fresh issue of 80,00,000 share warrants to promoter and non promoter group subject to necessary approvals. |
| Jan 04, 2017 | Others | 1. Withdrawal of entire preferential issue of 40,00,000 share warrants and in-principle application filed with the Stock Exchanges. |
| Nov 11, 2016 | Quarterly Results | - |
| Aug 11, 2016 | Quarterly Results | - |
| Jun 17, 2016 | Issue of Equity Shares | - |
| May 30, 2016 | Audited Results | - |
| Feb 11, 2016 | Quarterly Results | - |
| Nov 06, 2015 | Quarterly Results | - |
| Aug 12, 2015 | Quarterly Results | - |
| May 29, 2015 | Audited Results | Appointed M/s. A.K. Jain & Associates, Practicing Company Secretaries for the purpose of Secretarial Audit for the year 2015-16. |
| Mar 27, 2015 | Appointment of Women Director | - |
| Feb 12, 2015 | Quarterly Results | - |
| Nov 07, 2014 | Quarterly Results | - |
| Aug 07, 2014 | Quarterly Results | - |
| May 30, 2014 | Audited Results & Dividend | - |
| Feb 13, 2014 | Quarterly Results | - |
| Nov 13, 2013 | Quarterly Results | - |
| Aug 10, 2013 | Quarterly Results & Others | The Un-Audited Financial Results for the Quarter ending June 30, 2013. & To consider appointment of Additional Director. |
| May 20, 2013 | Audited Results & Dividend | - |
| Feb 09, 2013 | Quarterly Results | - |
| Nov 07, 2012 | Quarterly Results | - |
| Sep 15, 2012 | Allotment of Shares | inter alia, to consider Allotment of Shares pursuant to conversion of warrants into Shares, warrants allotted on March 17, 2011. |
| Aug 14, 2012 | Quarterly Results & Others | 1. Allotment of Shares pursuant to conversion of warrants into Shares, warrants allotted on March 17, 2011. 2. To fix date, time and venue of 17th Annual General Meeting of the members of the Company. |
| May 30, 2012 | Audited Results & Dividend | (Board meeting postponed from 28/05/2012 to 30/05/2012) |
| Feb 10, 2012 | Quarterly Results | - |
| Jan 13, 2012 | Allotment of Equity Shares / Warrants | To consider allotment of 9,00,000 Equity Shares and 25,00,000 Warrants & to consider the revised facilities offered by State Bank of India, Leather & International Branch, Chennai. |
| Nov 12, 2011 | Quarterly Results | - |
| Aug 24, 2011 | Allotment of Equity Shares | - |
| Aug 10, 2011 | Quarterly Results | - |
| May 30, 2011 | Audited Results | - |
| Mar 17, 2011 | Allotment of Equity Shares & Warrants | To consider the allotment of 15,00,000 Equity Shares and 23,18,000 Warrants, pursuant to in-principle approval from Stock Exchange vide their letter dated March 14, 2011. |
| Feb 12, 2011 | Quarterly Results | (Revised) |
| Dec 06, 2010 | Preferential Issue of Shares | To consider the matter of issue and allotment of the Equity Shares and Equity Warrants of the Company on preferential basis to Promoters and Other Investors. |
| Oct 22, 2010 | Quarterly Results | - |
| Jul 29, 2010 | Quarterly Results | - |
| May 28, 2010 | Audited Results & Others | The Board has considered the followings: 1. Decided Not to recommended Dividend. 2. Approved the listing of securities of the Company with the National Stock Exchange Ltd & Madras Stock Exchange Ltd. |
| Apr 26, 2010 | Others | For re-appointment of Mr. Bafna Mahaveer Chand & Mr. Paras Bafna as Managing Director & Whole Time Director of the Company respectively. |
| Jan 27, 2010 | Quarterly Results | - |
| Oct 28, 2009 | Quarterly Results | - |
| Nov 22, 2008 | To accept Resignation of Director | To accept resignation of Mr. Ratanchan Lodha directorship on the Board of the Company with effect from September 18, 2008. |
| Aug 20, 2008 | Audited Results | - |
| Jul 26, 2008 | Quarterly Results | - |
| Jul 04, 2008 | Others | The Company has completed Allotment of I.P.O. issued shares and also listing of shares with BSE. |
| Ex-Date | Bonus Ratio | Record Date |
|---|
26 Apr 2024
BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement Regarding Inauguration Of New Quality Control Laboratory Of Company
We are delighted to announce the inauguration of new State-of-the-Art Quality Control Laboratory of the Company.
24 Apr 2024
BAFNA PHARMACEUTICALS LTD. - 532989 - Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Period Ended 31St March, 2024
We are herewith submitting the Compliance Certificate under Regulation 7(3) of SEBI (LODR) Regulations, 2015 for the period ended 31st March, 2024.
23 Apr 2024
BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
We hereby inform that Mr. Vishnu Vasudeva Kuppa has resigned from the position of Company Secretary & Compliance officer of the Company with effect from 23rd April, 2024.
22 Apr 2024
BAFNA PHARMACEUTICALS LTD. - 532989 - Compliance Certificate Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended 31St March, 2024
We are herewith enclosing the Compliance Certificate issued under Regulation 40(9) of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 for the year ended 31st March, 2024.
15 Apr 2024
BAFNA PHARMACEUTICALS LTD. - 532989 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are herewith enclosing Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for Quarter ended 31st March, 2024.
25 Mar 2024
BAFNA PHARMACEUTICALS LTD. - 532989 - Closure of Trading Window
The Trading Window for the designated persons, connected persons, shall remain closed from Sunday, March 31, 2024, up to 48 hours after the declaration of Financial results of the Company by the Board of directors for the quarter and year ending March 31, 2024.
14 Feb 2024
BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Newspaper Publication
we have furnished herewith newspaper clippings of Un-audited Standalone Financial Results of the Company for the quarter and nine months ended December 31, 2023, which was approved by the Board in its meeting held on February 12, 2024, and published in the newspapers, namely in Makkal Kural (Tamil edition) and Business Standard (English edition) on Tuesday, February 13, 2024.
12 Feb 2024
BAFNA PHARMACEUTICALS LTD. - 532989 - Un-Audited Standalone Financial Results For The Quarter Ended December 31, 2023.
we wish to inform that at the meeting of the Board of Directors of the Company held today i.e., February 12, 2024, Monday, the results of the quarter ended on December 31, 2023, duly reviewed by Audit Committee, inter-alia has been considered and approved by the Board of Directors of the Company.
02 Feb 2024
BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for Intimation Of Meeting Of Board Of Directors - Approval Of Q3 FY24 Financial Results.
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 ,inter alia, to consider and approve A meeting of board of directors of the Company is scheduled to be held on Monday, February 12, 2024, inter-alia, to consider and approve the Un-Audited Standalone Financial Results of the Company for the third quarter of FY24 ended December 31, 2023, together with the 'Limited Review Report' for the said period.
11 Jan 2024
BAFNA PHARMACEUTICALS LTD. - 532989 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of SEBI(DP) Regulations, 2018, we enclosed herewith a certificate dated January 04, 2024, received from M/s Cameo Corporate Services Limited, the Registrar and Share Transfer Agent of the Company, confirming the dematerialization of share certificate within the prescribed timelines, during the quarter ended December 31, 2023.
